Prognostic impact of CD5 expression in diffuse large B‐cell lymphoma in patients treated with rituximab‐EPOCH

Objectives CD5‐positive (CD5+) diffuse large B‐cell lymphoma (DLBCL) represents 5%‐10% of all DLBCL cases, which has been associated with a poorer prognosis in patients treated with R‐CHOP. Prognostic impact of CD5 expression in patients with DLBCL treated with R‐EPOCH has not been evaluated. Method...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2017-04, Vol.98 (4), p.415-421
Main Authors: Thakral, Beenu, Medeiros, L. Jeffrey, Desai, Parth, Lin, Pei, Yin, C. Cameron, Tang, Guilin, Khoury, Joseph D., Hu, Shimin, Xu, Jie, Loghavi, Sanam, Hu, Bei, Oki, Yasuhiro, Li, Shaoying
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
B-cell lymphoma
Bcl-6 protein
CD5
CD5 antigen
CD5 Antigens - biosynthesis
Central nervous system
Cyclophosphamide - administration & dosage
diffuse large B‐cell lymphoma
Disease-Free Survival
Doxorubicin - administration & dosage
Etoposide - administration & dosage
Female
Fluorescence in situ hybridization
Gene Expression Regulation, Neoplastic
Humans
Immunotherapy
Ki67 index
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - metabolism
Lymphoma, Large B-Cell, Diffuse - mortality
Male
Medical prognosis
Middle Aged
Monoclonal antibodies
Multivariate analysis
Myc protein
Neoplasm Proteins - biosynthesis
Prednisone - administration & dosage
Prognosis
Rituximab
Rituximab - administration & dosage
R‐EPOCH
Survival Rate
Targeted cancer therapy
Vincristine - administration & dosage
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives CD5‐positive (CD5+) diffuse large B‐cell lymphoma (DLBCL) represents 5%‐10% of all DLBCL cases, which has been associated with a poorer prognosis in patients treated with R‐CHOP. Prognostic impact of CD5 expression in patients with DLBCL treated with R‐EPOCH has not been evaluated. Methods We studied 130 patients with de novo DLBCL who received frontline R‐EPOCH therapy. The clinicopathologic features and overall survival (OS) were compared between patients with CD5+ and CD5‐ DLBCL. MYC, BCL2, and BCL6 rearrangements were examined by fluorescent in situ hybridization. Results Sixteen (12.3%) of 130 DLBCLs were CD5+. Most clinicopathologic features including cell of origin and frequency of MYC, BCL2, and BCL6 rearrangements were similar between CD5+ and CD5− groups. Patients with CD5+ DLBCL, however, showed higher rate of central nervous system relapse (33.3% vs 15.6%; P
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.12847